Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAlexandar TzankovACApril ChiuMXMina L. Xu

Discussion

Loading...

Member takes

Overview

Hi-C sequencing demonstrates improved biomarker detection in diffuse large B-cell lymphoma, suggesting enhanced treatment options through targeted therapies.

Key Points

  • Hi-C sequencing revealed greater detection rates for DLBCL biomarkers compared to FISH.
  • FISH detected 76% of tested biomarkers while Hi-C achieved a 97% detection rate in the sample cohort.
  • Observational analysis using genomic rearrangements found additional biomarkers aiding DLBCL diagnosis.
  • This advancement supports enhanced precision treatment strategies but requires external validation for broader application.

Cite This Study

Tzankov et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e577https://doi.org/10.1182/blood-2025-3529
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hi-C Technology Reveals Actionable Gene Fusions and Rearrangements in Diffuse Large B-Cell Lymphoma Unidentified by Conventional FISH2025 · 2 citations
  2. 2Clinical use of genome-wide hi-c sequencing for assessment of structural variants in diffuse large B-cell lymphoma2025
  3. 3Application of hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms2025
  4. 4Comprehensive genomic profiling of diffuse large B cell lymphoma using targeted NGS: Insights into MYC, BCL2, and BCL6 rearrangements and beyond2025 · 1 citations
  5. 5Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling2025